Biktarvy, formally known as bictegravir sulfate, represents a effective single-tablet therapy for controlling HIV infection. This formula integrates three key antiviral components: bictegravir, emtricitabine, and tenofovir alafenamide. It works by inhibiting the virus's ability to replicate within the body, considerably lowering the viral burden.